Agenus Inc. (AGEN) Fair Value 2026

AGEN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 12 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-07-13, Agenus Inc. (AGEN) trades at $6.12, approximately 40% below CirclFi’s Bayesian DCF fair value of $10.21. QOC: 5.1/10. Value Trap Risk: 43/100 (WARN). 12/13 models active.

Key Facts

Ticker
AGEN
Price
$6.12
Quality Score
5.1/10
Value Trap Risk
43/100
Models Active
12/13
Last Updated
Strength: Earnings Power Value suggests +183.8% upside with 41% confidence
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($6.12)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Medium Conviction
$10.21 +66.8%
Earnings Power Value
Medium Conviction
$17.37 +183.8%
CUCE Ensemble
Low Conviction
$11.33 +85.1%
First Chicago
High Conviction
$2.54 -58.5%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Agenus Inc. (AGEN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Agenus Inc.'s intrinsic value is estimated at a composite fair value of $10.39. While the stock appears modestly undervalued at $6.12 (implied upside of +69.8%), our analysis suggests a thinner margin of safety across 8 of 12 bullish models. Notably, Regime Cross sees the most upside at +305.0% (fair value: $24.79), while Sentiment SOTP is the most conservative at -61.7% ($2.34). The spread between these extremes — +366.7% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About AGEN?

12 of 13 models are currently active for AGEN. Of these, 8 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates AGEN's intrinsic value at $10.21, implying +66.8% upside from the current price. See which stocks rank higher →

How Does AGEN Rank in Biotechnology?

Among 62 Biotechnology stocks, AGEN ranks #26 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Agenus Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating AGEN should weigh these sector-specific dynamics alongside our model-derived fair values.

Is AGEN a Value Trap?

CirclFi's Value Trap algorithm assigns AGEN a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Agenus Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Agenus Inc.'s fundamental quality profile registers 5.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +366.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AGEN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AGEN's 12 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Agenus Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

Read investment analysis: ADMA · ACAD · ALNY · ACRS · ABCL

See all Biotechnology stocks ranked →

Frequently Asked Questions About Agenus Inc.

What is Agenus Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Agenus Inc. (AGEN) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $10.21. The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AGEN overvalued or undervalued right now?

At $6.12, 8 of 12 active models suggest AGEN may be undervalued, while 4 indicate potential overvaluation. The assessment depends on which methodology best fits Agenus Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for AGEN?

Agenus Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AGEN?

CirclFi analyzes AGEN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is AGEN a value trap in 2026?

Agenus Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on AGEN.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access